Company news
Viridian Metals Inc (CSE:VRDN) news
Viridian Metals Inc news releases on 6ix. Latest, Oct 2, 2026: Viridian Intersects Sulphides Throughout 3 km of Step-Out Drilling at Kraken Main
Press releases & updates
Viridian Intersects Sulphides Throughout 3 km of Step-Out Drilling at Kraken Main
October 1, 2026
Viridian Metals Announces Initial Exploration Target at Kraken Main Zone
September 14, 2026
Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main
September 8, 2026
Viridian Metals Intersects Over 50 Metres of Mineralization from Surface at Kraken Main
September 7, 2026
Viridian Metals Announces Closing of Non-Brokered Private Placement and Market Making Agreement with Independent Trading Group
September 4, 2026
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
September 2, 2026
Viridian Metals Announces $1.0 Million Private Placement
August 24, 2026
Viridian Metals Reports Continuation of Massive Sulphides at Kraken Main; First Assays Pending
August 5, 2026
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
August 6, 2026
Viridian Metals Commences Trading on the OTCQB Venture Market Under the Symbol “VIRMF”
July 14, 2026
Viridian Metals Announces Results of Annual General and Special Meeting and Closing of Non-Brokered Private Placement
July 7, 2026
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa(TM) (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
June 26, 2026
Viridian Metals Commences 2026 Diamond Drill Program at the Kraken
June 8, 2026
Viridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill Program
June 4, 2026
Viridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel Project
May 18, 2026
Viridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special Meeting
May 14, 2026
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
May 6, 2026
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
May 5, 2026
Viridian Metals Clarifies Disclosure
April 15, 2026
Viridian Announces Market Services Agreement With Outside The Box Capital
April 15, 2026
Viridian Metals Secures $225,000 Maximum JEA Funding; Adopts Quarterly Reporting Exemption
April 8, 2026
Chablis Capital Corp. Enters into Definitive Agreement and Exchange Conditional Approval for Qualifying Transaction
April 1, 2026
Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
March 31, 2026
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL?1 Clinical Trial in Active Thyroid Eye Disease
March 30, 2026
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
Viridian Confirms Basin-Scale Plumbing Systems and Copper-Bearing Chemical Traps at the Sedna Project
February 18, 2026
Viridian Continues to Define Large-Scale, Near-Surface Mineralization at Kraken
February 5, 2026
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 8, 2026
Viridian Therapeutics Prepares for Transformational 2026
January 6, 2026
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
December 22, 2025
Viridian Releases Initial 2025 Drill Results Confirming Shallow, Continuous Sulphide Mineralization at Kraken
December 10, 2025
Viridian Metals Announces Closing of First Tranche of Financing and Short Form Vertical Amalgamation
December 2, 2025
Viridian Metals Launches Financing to Build on Positive Market Momentum
November 7, 2025
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
November 5, 2025
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
November 3, 2025
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
October 21, 2025
Viridian Therapeutics Announces Proposed Underwritten Public Offering
October 21, 2025
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
October 20, 2025
Chablis Capital Corp. Announces Proposed Qualifying Transaction with Viridian Metals Ireland Limited
September 29, 2025
VIRIDIAN METALS INTERSECTS MASSIVE SULFIDES IN FIRST HOLES AT KRAKEN
September 24, 2025
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
September 15, 2025
VIRIDIAN METALS COMMENCES DRILLING AT KRAKEN MAIN ZONE
August 25, 2025
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
August 6, 2025
Viridian Metals Outlines Basin-Scale Copper Targets and Structural Controls at Sedna and Results of AGSM
July 31, 2025
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
July 30, 2025
Viridian Metals Announces Annual General and Special Meeting
July 9, 2025
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 3, 2025
Viridian Metals Appoints Stacie Jones to Board of Directors
June 16, 2025
Viridian Metals Closes Final Tranche of Oversubscribed Financing
June 5, 2025
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
May 30, 2025